Potential role of lampalizumab for treatment of geographic atrophy

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 1049-1056

  Rhoades, William ^a   Dickson, Drew ^a   Do, Diana V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Age related macular degeneration; AMD; Complement inhibition

Indexed keywords

RETRACTED ARTICLE; REVIEW;

EID: 84934756694     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S59725     Document Type: Review

References (32)

1. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485.
2. Bressler NM, Bressler SB, Congdon NG, et al; Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003;121(11):1621-1624.
3. Lindblad AS, Lloyd PC, Clemons TE, et al; Age-Related Eye Disease Study Research Group. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol. 2009;127(9):1168-1174.
4. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
5. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
6. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
7. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014.
8. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-1436.
9. Chew EY, Clemons T, SanGiovanni JP, et al; AREDS2 Research Group. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012;119(11):2282-2289.
10. Sunness JS, Rubin GS, Applegate CA, et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmology. 1997;104(10):1677-1691.
11. Sunness JS, Applegate CA. Long-term follow-up of fixation patterns in eyes with central scotomas from geographic atrophy that is associated with age-related macular degeneration. Am J Ophthalmol. 2005;140(6):1085-1093.
12. Sunness JS, Margalit E, Srikumaran D, et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology. 2007;114(2):271-277.
13. Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. 2014;15:151-171.
14. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385-389.
15. Schramm EC, Clark SJ, Triebwasser MP, Raychaudhuri S, Seddon JM, Atkinson JP. Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol Immunol. 2014;61(2):118-125.
16. Clark SJ, Perveen R, Hakobyan S, et al. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem. 2010; 285(39):30192-30202.
17. Sofat R, Casas JP, Webster AR, et al. Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol. 2012;41(1):250-262.
18. Fuse N, Mengkegale M, Miyazawa A, et al. Polymorphisms in ARMS2 (LOC387715) and LOXL1genes in the Japanese with age-related macular degeneration. Am J Ophthalmol. 151(3):550-556.
19. Cheng Y, Huang L, Li X, Zhou P, Zeng W, Zhang C. Genetic and functional dissection of ARMS2 in age-related macular degeneration and polypoidal choroidal vasculopathy. PLoS One. 2013;8(1):e53665.
20. Schubert HD, et al. Retina and vitreous. In: Basic and Clinical Science Course. American Academy of Ophthalmology, 2013-2014:64.
21. Andreoli TE. Cecil's Essentials of Medicine, ed. Thomas E Andreoli et al. Philadelphia: Saunders, 2004:804-807.
22. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14(7):835-846.
23. Charbel Issa P, Chong NV, Scholl HP. The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):163-174.
24. Caire J, Recalde S, Velazquez-Villoria A, et al. Growth of geographic atropy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration. JAMA Ophthalmol. 2014;132(5):528-534.
25. Weber BH, Charbel Issa P, Pauly D, et al. The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int. 2014; 111(8):133-138.
26. Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5):1079-1091.
27. Yehoshua Z, Garcia Filho CAA, Gregori G, et al. Systemic complement inhibition with eculizumab for the treatment of GA in AMD patients: the COMPLETE study. Presented at the 2012 Annual Meeting of the Association for Research in Vision and Ophthalmology [ARVO], May 6-10, 2012, Fort Lauderdale, FL, USA. Abs. 2046.
28. Do DV, Pieramici DJ, van Lookeren Campagne M, et al; Phase Ia Investigators. A phase ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy. Retina. 2014;34(2):313-320.
29. Volanakis JE, Narayana SV. Complement factor D, a novel serine protease. Protein Sci. 1996;5(4):553-564.
30. Zipfel PF, Lauer N, Skerka C. The role of complement in AMD. Adv Exp Med Biol. 2010;703:9-24.
31. Stanton CM, Yates JR, den Hollander AI, et al. Complement factor D in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011; 52(12):8828-8834.
32. Williams DF, Yaspan B, Zhengrong L, et al. Lampalizumab (anti-factor D) in Geographic Atrophy: the MAHALO Phase II Results. Presented at the 2013 American Society of Retina Specialists (ASRS) Meeting, August 27, 2013, Toronto, ON, Canada.